Detalhe da pesquisa
1.
Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
Eur J Cancer
; 75: 73-82, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28222309